X

Trial Profile

Efficacy of ibritumomab tiuxetan (Zevalin) following remission induction therapy for relapse of follicular lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Nov 2015

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibritumomab tiuxetan (Primary)
Indications Follicular lymphoma
Focus Therapeutic Use

Most Recent Events

14 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
21 Jun 2012 Actual initiation date (Jun 2012) added as reported by University Hospital Medical Information Network - Japan record.
21 Jun 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com